Anti-D Rho immunoglobulin - Mitsubishi TanabeAlternative Names: Anti-D Human Immunoglobulin; Dry anti-Rho(D) immune human globulin
Latest Information Update: 25 May 2011
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Immunoglobulins
- Mechanism of Action Immunoglobulin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemolytic disease of newborn